Clinical Trials Browser

Phase 2 × Terminated × idelalisib × Clear all

NCT03890289 2024-11-21

GAUDEALIS

Phase 2 Terminated

5 enrolled 13 charts

Lymphoma, Follicular

NCT04699461 2023-10-23

LOTIS-6

Phase 2 Terminated

6 enrolled 9 charts

Lymphoma, Lymphoma, Follicular

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01796470 2020-06-02

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Phase 2 Terminated

66 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02258529 2019-05-14

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Phase 2 Terminated

10 enrolled 10 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02044822 2018-11-19

Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion

Phase 2 Terminated

102 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02439138 2017-01-11

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Phase 2 Terminated

5 enrolled 8 charts

Waldenstrom Macroglobulinemia